According to Orexo, a dry powder formulation of an intranasal influenza vaccine formulated with the company’s AmorphOX powder engineering platform has produced a similar immune response in rats compared to a liquid formulation of the same vaccine. The company said that the proof of concept study demonstrated strong mucosal immune response in the nose and in the lung as well as a strong systemic response for both formulations.
In December 2024, Orexo and Abera Biosciences announced that they had partnered for development of nasal vaccines based on Orexo particle engineering technology and Abera’s BERA vaccine technology. Orexo’s pipeline also includes dry powder intranasal naloxone, nalmefene, and epinephrine.
Orexo Senior VP and Head of R&D Robert Rönn commented, “We are pleased by these results providing us with important proof of concept data for a vaccine formulated in our proprietary powder-based drug delivery technology AmorphOX. The potential benefits from formulating vaccines in powder form are significant, as they can reach so many more patients worldwide. The study results represent an important milestone in our continued efforts to develop new and innovative drugs.”
Abera Bioscience Chief Scientific Officer Mats Lundgren said, “It is very encouraging to see that our vaccines perform well in both liquid and powder forms. Powder formulations offer significant advantages in future pandemic scenarios, particularly in terms of simplified logistics, thermal stability, and the potential for self-administration during mass vaccination campaigns. Orexo’s AmorphOX technology is an innovative platform that appears to preserve the immunogenic properties of our vaccine.”
Read the Orexo press release
